Skip to main
NAGE

ChromaDex Corp (NAGE) Stock Forecast & Price Target

ChromaDex Corp (NAGE) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Niagen Bioscience is expected to see a boost in its financial performance in the coming quarters thanks to the launch of Niagen Plus, its clinician-directed telehealth platform, which allows patients to access prescription-only Niagen from home. This program, along with the potential introduction of a pen-like autoinjector and the recent establishment of a United States Pharmacopeia monograph for Niagen, could further accelerate the company's commercial uptake in a lucrative and rapidly growing market segment. Additionally, the recent lawsuit against regulators and potential future removal of competing NMN-based products could benefit Niagen Bioscience's sales ramp, while its strong financial profile with no debt and expanding EBITDA margins provide further support for a positive outlook.

Bears say

Niagen Bioscience is heavily reliant on the success and reputation of their flagship product, TruNiagen, and the supplements industry is highly competitive with larger and more established brands. Additionally, changes in government regulations and potential stock dilution risks could also impact the company's performance and shareholder value. Overall, these factors make the outlook for Niagen Bioscience's stock uncertain and potentially risky from a financial analyst's perspective.

ChromaDex Corp (NAGE) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ChromaDex Corp (NAGE) Forecast

Analysts have given ChromaDex Corp (NAGE) a Strong Buy based on their latest research and market trends.

According to 2 analysts, ChromaDex Corp (NAGE) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ChromaDex Corp (NAGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.